Insider Transactions in Q1 2023 at Ultragenyx Pharmaceutical Inc. (RARE)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2023
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,161
-5.33%
|
$142,245
$45.25 P/Share
|
|
Mar 01
2023
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,663
+16.91%
|
-
|
|
Mar 01
2023
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,881
-7.67%
|
$174,645
$45.25 P/Share
|
|
Mar 01
2023
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,663
+5.0%
|
-
|
|
Mar 01
2023
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,333
-5.78%
|
$59,985
$45.65 P/Share
|
|
Mar 01
2023
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
100
-0.43%
|
$4,500
$45.65 P/Share
|
|
Mar 01
2023
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,590
+24.69%
|
-
|
|
Mar 01
2023
|
Thomas Richard Kassberg CBO & EVP |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,394
-1.36%
|
$152,730
$45.65 P/Share
|
|
Mar 01
2023
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
1,968
-0.78%
|
$88,560
$45.27 P/Share
|
|
Mar 01
2023
|
Thomas Richard Kassberg CBO & EVP |
BUY
Grant, award, or other acquisition
|
Direct |
24,663
+4.58%
|
-
|
|
Mar 01
2023
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,664
-6.01%
|
$164,880
$45.25 P/Share
|
|
Mar 01
2023
|
Erik Harris EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,663
+16.49%
|
-
|
|
Mar 01
2023
|
Emil D Kakkis President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,140
-2.62%
|
$726,300
$45.65 P/Share
|
|
Mar 01
2023
|
Emil D Kakkis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
54,916
+4.24%
|
-
|
|
Mar 01
2023
|
John Richard Pinion |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,014
-5.01%
|
$180,630
$45.65 P/Share
|
|
Mar 01
2023
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
3,755
-4.47%
|
$168,975
$45.26 P/Share
|
|
Mar 01
2023
|
John Richard Pinion |
BUY
Grant, award, or other acquisition
|
Direct |
24,663
+12.45%
|
-
|
|
Mar 01
2023
|
Dennis Karl Huang |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,599
-14.07%
|
$476,955
$45.65 P/Share
|
|
Mar 01
2023
|
Dennis Karl Huang |
SELL
Open market or private sale
|
Direct |
389
-0.51%
|
$17,505
$45.65 P/Share
|
|
Mar 01
2023
|
Dennis Karl Huang |
BUY
Grant, award, or other acquisition
|
Direct |
24,663
+13.62%
|
-
|
|
Feb 28
2023
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
639
-3.95%
|
$27,477
$43.4 P/Share
|